A Brief Introduction of CD19 CAR-T Therapy

1. A Brief Introduction of CD19 CAR-T Therapy https://www.creative-biolabs.com/car-t/

2. CD19 The CD19 chimeric antigen receptors (CARs) are fusion proteins expressed on the surface of T cells by gene recombination technology, which combines a hinge region, a transmembrane domain, and one or more intracellular T cells that will specifically recognize the single-chain variable region and the extracellular domain of antibodies of CD19 by stimulating or co-stimulatory molecules.

3. When the gene sequences constituting the CARs molecule are transferred into T cells by genetic modification, the expression of CD19 CARs in T cells alters the specificity of the T cells to directly act on the target cells expressing CD19. Normally, CD19 CAR-T cells are delivered to patients after chemotherapeutic treatment with lymphocytic clearance in vivo, and the clinical effect of CD19-positive tumor cell lysis occurs when CAR-T cells are accumulated in large amounts in vivo for 2-3 weeks

4. Side Effects This treatment may cause the patient to develop cytokine release syndrome (CRS). The main clinical manifestations of CRS include fever, hypotension, capillary exudation, coagulopathy, organ failure, and neurotoxicity. The main cause of CRS is the increase in serum cytokine concentrations such as IL-6 and gamma interferon. Cellular immunotherapy of CD19 CAR-T has shown very promising results in relapsed B-cell acute lymphoblastic leukemia and has also shown encouraging results in the treatment of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

5. 1 Although CD19 CAR T immunotherapy is still immature, many research centers have begun to accumulate and report on the important experience of CAR-T cells in the treatment of B-cell malignancies related to production and effective delivery of CAR-T cells. We hope to find out the main influencing factors affecting the outcome of CAR-T cell immunotherapy by comparing different clinical trial data. 2 It should be noted that the production strategy including the separation and stimulation of T cells, the design of CAR structures, the transduction of CAR T gene, and the composition of cells and the number of amplifications to be prepared for input into patients are all different in different research centers.

6. Conclusions Numerous preclinical studies of CAR-T cell therapy have demonstrated that the design of CAR T cell structure, the selection of single-chain variable domains, the length and composition of extracellular hinge regions, and the selection of intracellular co-stimulatory molecular sequences as a model system for CAR produce a very important influence on the clinical effect of CAR T. Obviously, in addition to the production and delivery of CAR-T cells, various factors such as co-stimulatory molecules or inhibitory molecules on the surface of tumor cells will affect their therapeutic outcome, and thus the choice of costimulatory molecules will be different in different clinical contexts.

7. About Creative Biolabs As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.

8. Contact us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

9. Thank You https://www.creative-biolabs.com/car-t/